NICE decision to restrict Alzheimer's drugs 
Please Help Support Alzheimer's Research Today!
Your Alzheimer's donation will help billions live without it. Donate online now
There has been widespread condemnation of the National Institute for Health and Clinical Excellence's (NICE) decision to restrict Alzheimer's drugs that cost just £2.50 a day on the NHS.
Following a ruling by the Court of Appeal in May 2008, NICE was ordered to release the health economic model used to make the decision to key stakeholders. Alzheimer's Society has reviewed the calculations and submitted a detailed analysis to NICE. The charity has today appealed for NICE to review its decision on Alzheimer's drugs.
Neil Hunt, Chief Executive of Alzheimer's Society, says: "We have always argued that the way NICE calculated the cost effectiveness of Alzheimer's drugs was fundamentally flawed. Now that we have examined NICE's calculations first hand and taken expert advice, Alzheimer's Society remains convinced that denying people with Alzheimer's effective drugs makes no sense".
NICE must urgently review its decision. One in three people over 65 will die with dementia; the current state of dementia care and treatment in the UK is a national scandal.' Alzheimer's Society cannot release its full response to NICE due to NICE's confidentiality rules. However, previously the charity has highlighted the following concerns about the way cost effectiveness is calculated:
- NICE assumes everyone who starts treatment continues on it. In reality, only those who benefit from drugs would stay on them.
- NICE has drastically underestimated the cost savings to the State of people receiving treatment and remaining active in the community (rather than cared for in homes or hospitals)
- NICE does not take into account the full benefit drug treatment can have on a carer's quality of life.
In October 2008, the House of Lords denied NICE the right to appeal the high court decision which ordered it to release a copy of the executable model. ...http://www.medicalnewstoday.com
Posted YVN
Слушать Радио Радио Столица
Your Alzheimer's donation will help billions live without it. Donate online now
Thousands of people with early stage Alzheimer's are being denied access to the only drugs for the disease due to fundamental flaws in the way their cost effectiveness has been calculated.
There has been widespread condemnation of the National Institute for Health and Clinical Excellence's (NICE) decision to restrict Alzheimer's drugs that cost just £2.50 a day on the NHS.
Following a ruling by the Court of Appeal in May 2008, NICE was ordered to release the health economic model used to make the decision to key stakeholders. Alzheimer's Society has reviewed the calculations and submitted a detailed analysis to NICE. The charity has today appealed for NICE to review its decision on Alzheimer's drugs.
Neil Hunt, Chief Executive of Alzheimer's Society, says: "We have always argued that the way NICE calculated the cost effectiveness of Alzheimer's drugs was fundamentally flawed. Now that we have examined NICE's calculations first hand and taken expert advice, Alzheimer's Society remains convinced that denying people with Alzheimer's effective drugs makes no sense".
NICE must urgently review its decision. One in three people over 65 will die with dementia; the current state of dementia care and treatment in the UK is a national scandal.' Alzheimer's Society cannot release its full response to NICE due to NICE's confidentiality rules. However, previously the charity has highlighted the following concerns about the way cost effectiveness is calculated:
- NICE assumes everyone who starts treatment continues on it. In reality, only those who benefit from drugs would stay on them.
- NICE has drastically underestimated the cost savings to the State of people receiving treatment and remaining active in the community (rather than cared for in homes or hospitals)
- NICE does not take into account the full benefit drug treatment can have on a carer's quality of life.
In October 2008, the House of Lords denied NICE the right to appeal the high court decision which ordered it to release a copy of the executable model. ...http://www.medicalnewstoday.com
Aker BioMarine says Krill oil key in 2009
A European supplier of health supplements says that the launch of a branded Krill oil product onto the Norwegian market will be a key launch for 2009 ahead of potential further rollouts in Europe, the US and Asia. ...http://www.nutraingredients.com
posted by Valery Yermalitsky at
5:51 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home